Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8493861 | 1.00 | CTSS (0.55) | CTSSCTSLCTSBCTSKPSMB8 | |
| SCHEMBL28707519 | 0.91 | CASP1 (0.60) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL28707521 | 0.91 | CASP1 (0.60) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL8496964 | 0.88 | SMN1; SMN2 (0.61) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL36611 | 0.88 | SMN1; SMN2 (0.61) | CTSSCTSLCTSBCTSKMME | |
| Hydroxyamine SCHEMBL9197242 | 0.87 | SMN1; SMN2 (0.60) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL7540896 | 0.86 | CTSS (0.54) | CTSSCTSLCTSBCTSKPSMB8 | |
| SCHEMBL13884485 | 0.86 | CTSS (0.58) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL14433709 | 0.86 | CTSS (0.58) | CTSSCTSLCTSBCTSKMME | |
| SCHEMBL1122463 | 0.86 | CTSS (0.58) | CTSSCTSLCTSBCTSKMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12588686-B2 | Method for producing modified pea protein | AJINOMOTO CO., INC. (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-3930478-B1 | STABLE PROTEIN FORMULATIONS | AMANO ENZYME USA CO LTD (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023190734-A1 | METHOD FOR PRODUCING PLANT PROTEIN-CONTAINING LIQUID FOOD | 不二製油グループ本社株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230210130-A1 | IMPROVING TEXTURE OF PROTEIN | AMANO ENZYME EUROPE LTD. (GB) | 2023-07-06 | — | — | US | disclosed |
| EP-4162806-A1 | IMPROVING TEXTURE OF PROTEIN | Amano Enzyme Inc. (JP) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867144-A | Taste improvement of protein | 天野酶制品株式会社 | 2023-03-28 | — | — | CN | disclosed |
| US-20220338503-A1 | METHOD FOR PRODUCING PLANT PROTEIN CONCENTRATE | AMANO ENZYME INC (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-4029947-A1 | METHOD FOR PRODUCING PLANT PROTEIN CONCENTRATE | Amano Enzyme Inc. (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-20220142210-A1 | STABLE PROTEIN FORMULATIONS | AMANO ENZYME USA CO., LTD. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3995000-A1 | METHOD FOR PRODUCING MODIFIED PEA PROTEIN | Ajinomoto Co., Inc. (JP) | 2022-05-11 | — | — | EP | disclosed |
| CN-114258268-A | Method for producing plant protein concentrate | 天野酶制品株式会社 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021049591-A1 | METHOD FOR PRODUCING PLANT PROTEIN CONCENTRATE | 天野エンザイム株式会社 | 2021-03-18 | — | — | WO | disclosed |
| EP-0693556-B1 | TRANSGLUTAMINASE ORIGINATING IN JAPANESE OYSTER | AJINOMOTO KK (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-0379606-B2 | Novel transglutaminase | AJINOMOTO KK (JP) | 1999-07-28 | — | — | EP | disclosed |
| US-5736356-A | CULTIVATION OF TRANSFORMED CELL AS GELLING AGENT FOR GELATION OF PROTEIN SOLUTION OR SLURRY | AJINOMOTO CO., INC. (JP) | 1998-04-07 | — | — | US | disclosed |
| EP-0693556-A1 | TRANSGLUTAMINASE ORIGINATING IN JAPANESE OYSTER | Ajinomoto Co., Inc. (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-5252469-A | Culturing the microorganism in the absence of calcium ion | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5156956-A | Derived from microorganism; catalyzes protein gelation in absence of calcium | AJINOMOTO CO., INC. (JP) | 1992-10-20 | — | — | US | disclosed |
| US-5055310-A | Reacting soy milk with solidifying agent and transglutaminase enzyme as catalyst | AJINOMOTO CO., INC. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0379606-A1 | Novel transglutaminase | AJINOMOTO CO., INC. (JP) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12588686-B2 | Method for producing modified pea protein | GLUL, ASNS, UBA2 | CTSS 1046/4885CTSL 992/4885CTSB 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.